Skip survey header
Low Vision Mode

Registration for COVID-19 Monoclonal Antibody Allocation


Thank you for your interest in becoming a provider of monoclonal antibodies, which are investigative medications recently authorized by the FDA for emergency use for the treatment of mild to moderate COVID-19.  Until the nationwide supply is sufficient, Texas will allocate the available doses of bamlanivimab and casirivimab/imdevimab (Regeneron cocktail).

As of December 23, the federal government is allowing allocation of both bamlanivimab and casirivimab/imdevimab to facilities other than acute care hospitals and their associated facilities. Acute care hospitals are automatically eligible for allocation and do not need to complete this survey.
  • These medications are administered via IV infusion. Please read the EUA and additional information for the available medications so that you are familiar with the indications and contraindications and can confirm that your facility serves the patient profile.
  • This survey is to register your facility’s interest in being allocated MONOCLONAL ANTIBODY treatments.  This is NOT for vaccine.  If you wish to register as a COVID-19 vaccine provider, please go here.
  • If your facility is not prepared to receive and administer the therapeutics as soon as they are available to you (i.e. process has been established, no pending administrative approvals, etc.), please return to this survey when the facility is ready.
  • The facility's National Provider Identifier (NPI) is required.
  • Either a pharmacy license number OR a physician's medical license is required for this survey. 
    • If your facility chooses to ship the medications to your partner pharmacy, please enter the license number and name of your contract pharmacy. 
    • For facilities without a pharmacy, either their own or contracted, who wish to ship to your facility may use an authorizing physician. Enter the full name and license number of a responsible physician.  The authorizing physician must sign and submit a Letter of Authorization to the distributor.
  • For the duration of the allocation process of the limited supply of therapeutics, facilities must record the treatments administered in ImmTrac2, the Texas immunization Registry. In accordance with Texas Health and Safety Code Sec. 161.00705, recording administration of Antiviral, Immunization and other Medication for disasters and emergencies must be entered in the Texas Immunization Registry, ImmTrac2.  If your facility is not already a registered user of ImmTrac2, please register here.
  • Facilities must also report daily counts of patient courses administered and on-hand inventory via the TDEM/DSHS Reporting portal.
  • Facilities may transfer the medication to another facility.  Please make sure that the receiving facility is aware of the reporting requirements.
  • Allocations are done weekly and the distributor, AmerisourceBergen, will contact you prior to shipping the medication, which requires refrigeration.

Email questions to DSHS Therapeutics.